YY-20394

· Shanghai YingLi Pharmaceutical Co. Ltd.

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for YY-20394, covering 2020-05-07 to 2024-06-13. Get the full timeline:

Most recent: Clinical Trial Update: A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies [Phase 1]